Showing 1791-1800 of 10612 results for "".
From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
https://reachmd.com/programs/cme/from-data-to-debate-global-perspectives-on-hrher2-mbc-care/37268/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
https://reachmd.com/programs/cme/unmet-needs-in-endocrine-therapy-rethinking-the-hrher2-mbc-treatment-roadmap/39797/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
https://reachmd.com/programs/cme/beyond-fulvestrant-oral-serds-redefining-er-targeting/39800/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/Engaging Your Patient: Shared Decision-Making in HF With Preserved Ejection FractionIgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/Examine updated KDIGO 2025 IgAN guidelines and the new approach to managing proteinuria and slowing kidney function decline.Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
https://reachmd.com/programs/cme/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Asia-Pacific: Practice Beyond Borders
https://reachmd.com/programs/cme/spotlight-on-asia-pacific-practice-beyond-borders/39810/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
https://reachmd.com/programs/cme/doublet-or-triplet-a-case-based-debate-in-first-line-choices-for-hrher2-mbc/39806/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Latin America: Closing the Gap
https://reachmd.com/programs/cme/spotlight-on-latin-america-closing-the-gap/39809/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
https://reachmd.com/programs/cme/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.